Loading, please wait....jpg)
.jpg)
The Premier April 24, 2024 CE webinar will be held from 12 - 1 pm EST. We are pleased to provide one (1) 60-minute application-based, ACPE-accredited CE activity to pharmacists and pharmacy technicians.
BUPRENORPHINE IN THE MANAGEMENT OF OPIOID USE DISORDER (OUD): UPDATES ON ROLE IN THERAPY, ACCESSIBILITY, AND NOVEL DOSING STRATEGIES
SPEAKER: Michael Biglow, PharmD, BCPS, BCPP, Clinical Manager, Inpatient Pharmacy Services, Presbyterian Healthcare Services, Albuquerque, NM
ACPE Universal Activity Number 0122-0000-24-010-L08-P/T [0.1 CEU] [1 Contact Hr.] (Application-based)
Date: Apr 24, 2024 12:00 PM - 01:00 PM
Fee
CE Hours
CE Units
Registration closes on Apr 24, 2024 12:10 PM
Activity Type
- Application
Target Audience(s)
- Pharmacists
- Pharmacy Technicians
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
Support/Credits
Registration closes on Apr 24, 2024
at 12:10 PM
Registration Closed
Objectives
- Review the unique properties and advantages of buprenorphine in the management of OUD
- Analyze novel dosing strategies for induction of high-risk patients
- Discuss the potential impact of the MAT Act (i.e. removal of the DATA 200 waiver) on patient access to buprenorphine
- Evaluate patient-specific parameters when considering long-acting injectable formulations
- Develop management strategies for use of buprenorphine in special populations (e.g. pediatrics, obstetrics)
Speaker(s)/Author(s)
|
Michael Biglow, PharmD, BCPS, BCPP
|